Although elevated levels of aldosterone are associated with vascular inflammation, the proinflammatory pathways of aldosterone are not completely defined. We now show that aldosterone triggers endothelial cell exocytosis, the first step in leukocyte trafficking. Exogenous aldosterone stimulates endothelial exocytosis of Weibel-Palade bodies, externalizing P-selectin and releasing von Willebrand factor. Spironolactone, a nonselective mineralocorticoid receptor (MR) blocker, antagonizes aldosterone-induced endothelial exocytosis. Knockdown of the MR also decreases exocytosis, suggesting that the MR mediates exocytosis. Aldosterone triggers exocytosis within minutes, and this effect is not inhibited by actinomycin D, suggesting a nongenomic effect of aldosterone. Aldosterone treatment of endothelial cells increases leukocyte adherence to endothelial cells in culture. Taken together, our data suggest that aldosterone activates vascular inflammation in part through nongenomic, MR-mediated pathways. Aldosterone antagonism may decrease vascular inflammation and cardiac fibrosis in part by blocking endothelial exocytosis.
A ldosterone regulates Na ϩ and K ϩ homeostasis, in part by modulating Na ϩ resorption in the kidney. The mineralocorticoid receptor (MR) in epithelial cells lining the distal nephron mediates aldosterone regulation of electrolytes. However, aldosterone may have additional physiological effects, such as increasing fibrosis, modulating oxidative stress, and triggering vascular inflammation (1) (2) (3) (4) (5) (6) (7) .
Hyperaldosteronism is associated with vascular inflammation (1, 2, (8) (9) (10) (11) (12) (13) (14) . Aldosterone infusion induces leukocyte infiltration into arteries of rats and increases the expression of proinflammatory markers (15, 16) . Mineralocorticoid receptor (MR) antagonists decrease monocyte infiltration into the vascular wall in hypertensive rats, in rats treated with aldosterone, and in hypertensive mice (17) (18) (19) (20) (21) . Clinical studies also show that aldosterone increases markers of vascular inflammation. Patients with primary hyperaldosteronism have increased inflammatory biomarkers (22) . Infusion of aldosterone increases IL-6 and IL-12 levels in humans (23, 24) . Conversely, MR antagonists decrease markers of oxidative stress and acute-phase reactants in humans (25) . Thus animal and clinical data suggest that aldosterone promotes vascular inflammation.
The mechanisms by which aldosterone affects vascular inflammation are not fully elucidated. Aldosterone interacting with the MR activates the transcription of a set of proinflammatory genes (26, 27) . For example, aldosterone increases vascular smooth muscle cell expression of IL-6, PAI-1, and CTLA-4. Furthermore, aldosterone increases oxidant stress, which in turn promotes vascular inflammation. In particular, aldosterone increases expression of the NADPH oxidase subunits p22phox and gp91phox in the aorta, leading to an increase in reactive oxygen species (28, 29) . Aldosterone also decreases endothelial expression of glucose-6-phosphate dehydrogenase (G6PD), leading to increased oxidant stress and decreased nitric oxide (NO) levels (30) . Finally, aldosterone stimulates endothelial transcription of the proinf lammator y intercellular adhesion molecule-1 (ICAM-1) (31).
In addition to its transcriptional effects, aldosterone can also promote inflammation through nontranscriptional pathways (5, (32) (33) (34) (35) . Aldosterone rapidly activates mitogen-activated protein kinase (MAPK) signaling in fibroblasts (36, 37) . Furthermore, aldosterone rapidly activates calcium influx and protein kinase C (PKC), cAMP levels and protein kinase A (PKA), and protein kinase D (PKD) signaling pathways (32, 34, (38) (39) (40) .
We hypothesized that aldosterone promotes vascular inflammation in part by triggering endothelial exocytosis. A variety of vascular agonists can bind to endothelial cell receptors and activate the secretion of endothelial granules, also called WeibelPalade bodies (WPBs) (41, 42) . WPB contain a variety of proinflammatory mediators, such as P-selectin, and prothrombotic signals, such as von Willebrand factor (vWF). Exocytosis leads to the translocation of P-selectin from the interior of the granule to the exterior surface of the endothelial cell. P-selectin then interacts with its receptor on the surface of leukocytes, mediating leukocyte rolling, the first step in leukocyte trafficking and vascular inflammation. Because hypertension is associated with vascular inflammation, it is possible that hypertensive messengers like aldosterone also stimulate vascular inflammation. In particular, because aldosterone leads to leukocyte infiltration, we hypothesized that aldosterone regulates one of the steps in leukocyte trafficking, such as endothelial exocytosis.
Aldosterone Rapidly Induces Endothelial Exocytosis. Aldosterone can regulate transcription over several hours, and aldosterone can also have rapid nongenomic effects. We measured the kinetics of the release of vWF following aldosterone treatment, and we found that aldosterone stimulates release of vWF within 10 min (Fig. 2A ). This effect is not transcriptional, as aldosterone stimulates vWF release even in cells treated with actinomycin D (Fig. 2B ).
Mineralocorticoid Receptor Mediates Aldosterone Activation of Endothelial Exocytosis. We next explored the role of the mineralocorticoid receptor (MR; also referred to as MLR, MCR, or NR3C2 gene product) in mediating aldosterone stimulation of endothelial exocytosis. Human aortic endothelial cells (HAEC) express MR by RT-PCR (Fig. 3A) and by immunoblotting (Fig.  3B) . We then used pharmacological and genetic techniques to define the role of the MR in mediating the effects of aldosterone on endothelial exocytosis.
First, we used siRNA to decrease MR expression in endothelial cells (Fig. 3C) . Knockdown of the MR decreases aldosterone's effect on exocytosis (Fig. 3D) . These genetic data suggest that MR mediates aldosterone induction of endothelial exocytosis.
Next, we pretreated endothelial cells with spironolactone, an inhibitor of the MR. Spironolactone inhibits aldosteronetriggered vWF release in a dose-dependent manner (Fig. 4A) . Spironolactone does not inhibit thrombin activation of exocytosis (Fig. 4B) . To confirm that the effects of spironolactone are specific for the MR, we also pretreated HAEC with tamoxifen, a selective estrogen receptor modulator, or mifepristone, a progesterone antagonist. These other inhibitors did not affect aldosterone stimulation of exocytosis (Fig. 4C ). These inhibitors alone have no affect on exocytosis (Fig. 4D) . Taken together, the pharmacological and genetic data suggest that the MR mediates aldosterone activation of vWF release. calcium signaling. We added the calcium ionophore A23187 at varying concentrations to HAEC and measured the release of vWF. Calcium ionophore increases exocytosis in a dosedependent manner [supporting information (SI) Fig. S1 ]. To define the pools of calcium that trigger exocytosis in response to aldosterone, we added aldosterone to endothelial cells incubated with normal media, calcium free media, or with 1,2-Bis[2-Aminophenoxy]ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA) (which disperses intracellular calcium storage pools). BAPTA decreases endothelial release of vWF (Fig.  S1 ), but removing extracellular calcium has no effect. The calmodulin antagonist trif luoperazine (TFP) inhibited aldo- sterone-triggered vWF release, suggesting that calmodulin may be involved in aldosterone signaling (Fig. S1 ). TFP alone did not affect exocytosis (Fig. S1 ). Taken together, these data suggest that intracellular calcium plays a critical role in aldosterone-triggered exocytosis.
Aldosterone Activates Leukocyte-Endothelial Interactions. We then measured the effect of aldosterone on leukocyte interactions with endothelial cells ex vivo. We pretreated HAEC with vehicle or spironolactone for 1 h, and then added vehicle or aldosterone or thrombin or thrombin receptor-activating peptide (TRAP) for 1 h; BCEF-loaded HL-60 cells were added to the endothelial cells, incubated at 4°C for 15 min, and then washed. The cocultured cells were then imaged with a digital camera. Few HL-60 cells adhere to control endothelial cells, but aldosterone increases the number of HL-60 cells adhering to the endothelial cells ( Fig. 5 A and B) . Pretreatment with spironolactone inhibits aldosterone-induced HL-60 adherence to HAEC (Fig. 5 A and  B) . To confirm that aldosterone triggers endothelial exocytosis of Weibel-Palade bodies and externalizes P-selectin, we pretreated endothelial cells with antibody to P-selectin before adding aldosterone. Antibody to P-selectin decreases HL-60 adherence to endothelial cells ( Fig. 5 C and D) . Taken together, these data show that aldosterone triggers leukocyte adherence to endothelial cells in a P-selectin-dependent manner.
Discussion
Summary. The major finding of our study is that aldosterone induces endothelial exocytosis, leading to leukocyte adherence to endothelial cells. Our data may partly explain why elevated aldosterone levels promote vascular inflammation.
Mineralocorticoid Receptor and Endothelial Exocytosis. Two lines of evidence suggest that the MR mediates aldosterone's effect on exocytosis. First, spironolactone inhibits exocytosis after aldosterone treatment (Fig. 4) . However, in theory, spironolactone might inhibit unidentified aldosterone receptors other than the MR. Second, direct siRNA targeting of MR also inhibits aldosterone activation of exocytosis (Fig. 3 ). Our findings support the studies of others showing that MR mediates vascular inflammation. For example, the MR antagonists decrease oxidative stress and vascular inflammation in animal models (17) (18) (19) (20) (21) 44) .
Aldosterone Activates Endothelial Exocytosis Through a Nongenomic
Effect. We find that aldosterone activates exocytosis within 10 min of application (Fig. 2 A) . Actinomycin D fails to block the effects of aldosterone (Fig. 2B ). This rapid effect suggests that aldosterone is signaling through previously synthesized messengers, rather than by regulating the transcription of proteins. Our data add to the growing literature describing rapid, nongenomic effects of aldosterone (2, 5, (32) (33) (34) (35) . For example, aldosterone activates signaling pathways such as PKA, PKC, PKD, MAPK, and the NADPH oxidase in vascular smooth muscle; and aldosterone activates phosphatidylinositol 3-kinase in endothelial cells (32, 34, (36) (37) (38) (39) (40) (45) (46) (47) . However, nongenomic effects of aldosterone can be mediated through either the MR or other unidentified proteins. For instance, aldosterone increases calcium signaling in vascular smooth muscle cells in an MR-independent manner (48) . In our studies, we used siRNA to show that the MR mediates aldosterone activation of endothelial exocytosis. Thus our studies show that aldosterone has a rapid and nongenomic effect on exocytosis, mediated in part by the MR.
Aldosterone and Thrombin Activate Secretion of Distinct Vesicles.
Endothelial granules are heterogeneous. Weibel-Palade bodies contain vWF, P-selectin, and other proteins. TPA appears to reside in vesicles distinct from Weibel-Palade bodies. Sucrose gradient centrifugation of human lung endothelial cells reveals TPA and vWF in different distributions (43) . The small GTP binding protein Rab3D regulates vWF release but not TPA release from endothelial cells (49) . Our findings support the idea that TPA and vWF are stored in separate vesicular compartments. We found that thrombin induces release of both TPA and vWF, but aldosterone selectively activates release of vWF but not TPA (Fig. 1C) .
Proinflammatory Effects of Aldosterone in Humans.
Although aldosterone increases vascular inflammation in animals and in humans, the precise mechanisms are not completely understood. Clinical studies show that hyperaldosteronism or infusion of aldosterone is associated with elevated levels of inflammatory biomarkers (22) (23) (24) . Conversely, aldosterone antagonists decrease inflammatory biomarkers in animals and humans (25, (50) (51) (52) . For example, eplerenone decreases plasma levels of proinflammatory cytokines such as MCP-1 or IL-8 (53) . Aldosterone may activate inflammation in vivo through a variety of mechanisms, inducing synthesis of new proinflammatory proteins, activating NADPH oxidase to produce superoxide, and decreasing glucose-6-phosphate dehydrogenase transcription. Our data suggest an additional new mechanism for the proinflammatory effects of aldosterone: aldosterone activates endothelial exocytosis, leading to increased leukocyte rolling along the vessel wall and vascular inflammation.
Experimental Procedures
Reagents. Aldosterone was purchased from Sigma. Human alpha-thrombin was purchased from Enzyme Research Laboratories. Thrombin receptor activating peptide (TRAP) was purchased from Bachem. Beta-estradiol, progesterone, spironolactone, tamoxifen, mifepristone, hydrocortisone, trifluoperazine, calcium ionophore A223187, and BAPTA/AM were purchased from Sigma. Mouse anti-P-selectin (CD62P) monoclonal antibody was purchased from BD Bioscience. Rabbit polyclonal antibody to human MR was from Santa Cruz (sc-11412) and was used at 1:200. Mouse inner medullary collecting duct cells were from American Type Culture Collection (CRL-2123).
PCR. PCR was performed on total RNA harvested from endothelial cells, using a hMR sense primer 5Ј-GAAGATGCATCAGTCTGCCA-3Ј and a hMR antisense primer 5Ј-AGTCCAGCAGCTTGGTCAGT-3Ј. The PCR consisted of a 2-min denaturing step at 95°C; followed by 36 cycles of denaturing at 95°C and annealing at 58°C and extending at 72°C; and finishing with an extension at 72°C for 5 min.
Cell Culture and Analysis of vWF Release. Endothelial exocytosis was performed as described previously (54) . HAEC were obtained from Lonza-Clonetics and grown in EGM-2 media supplemented with 2% serum and growth factors in a kit (Bullet Kit; Clonetics). Endothelial cells were purchased at passage 3. Exocytosis was measured in HAEC between passages 5 and 7. To measure the effect of VEGF on vWF release, HAEC were grown in EGM-2 media with growth factors, then washed and placed in EGM-2 media without growth factors and without serum, stimulated with various concentration of aldosterone. The amount of vWF released into the media was measured by an ELISA (American Diagnostica). Some HAEC were stimulated with thrombin, estrogen, progesterone, or hydrocortisone for up to 1 h at 37°C. The supernatant from each well was collected separately at certain defined time points, and the concentration of vWF released into the media was measured by an ELISA.
siRNA Knockdown of MR in Rndothelial Cells. Endothelial cells were electroporated with siRNA against MR (M-003425-01; Dharmacon) or a control siRNA (D-001206 -14; Dharmacon) using a nucleofector (Amaxa). Electroporated cells were incubated for 48 h and then stimulated with aldosterone or vehicle.
Mineralocorticoid Receptor Expression, Inhibition, and Specificity. HAEC were grown in EGM-2 media with growth factors, then washed and placed in EGM-2 media without growth factors or serum. The cells were pretreated with varying concentrations of the aldosterone antagonist spironolactone at 37°C for 1 h and then aldosterone at 10 Ϫ9 M was added for 1 h at 37°C. The supernatant from each well was collected separately and the concentration of vWF released into the media was measured by an ELISA. Mineralocorticoid receptor expression was demonstrated using RT-PCR. RNA was isolated from HAEC and HELA cells and a 3Ј gene-specific primer for the mineralocorticoid receptor gene was used for reverse transcription. The cDNA was then amplified using Taq polymerase and gene-specific forward and reverse primers. The samples both with and without primers were placed on a gel to show the MW of the specific isolated sequence present in both cell populations.
Calcium and Aldosterone-Mediated vWF Release. HAEC were grown in EGM-2 media with growth factors, then washed and placed in EGM-2 media without growth factors or serum. The calcium ionophore A23187 was then added at varying concentrations to HAEC at 37°Celsius for 1 h. The amount of vWF released into the media was then quantified using ELISA. HAEC were pretreated with either the intracellular calcium chelator BAPTA/AM at a concentration of 20 M and Dulbecco Modified Eagle's Medium (DMEM) or with calcium-free media and allowed to incubate for 30 min at 37°C. Aldosterone 10 Ϫ9 M was then added to the HAEC and placed in the incubator at 37°C for 1 h. The amount of vWF released into the supernatant was then measured with ELISA. The calmodulin antagonist trifluoperazine was used to determine the role of calmodulin in vWF release. HAEC were pretreated with trifluoperazine at varying concentrations at 37°C for 30 min. Then aldosterone 10 Ϫ9 M was added to the cells and placed in the incubator at 37°C for 1 h. The amount of vWF release in the supernatant was measured by ELISA.mbf.
Aldosterone-Mediated Leukocyte and Endothelial
Interactions. The human promyelocytic cell line HL-60 was obtained from the American Type Culture Collection. HAEC were pretreated with or without spironolactone 10 Ϫ7 M for 1 h at 37°C and then aldosterone (10 Ϫ9 M), thrombin 1 U/ml, or TRAP (10 Ϫ6 M) were added for 1 h. HL-60 cells were then loaded with BCEF-AM and cocultured with the HAEC. The cell mixtures were incubated at 4°C for 15 min, washed twice with HBSS, and then imaged with a digital fluorescent camera. HAEC were also treated with aldosterone (10 Ϫ9 M) or A223187 at 1 M for 1 h with or without antibody to P-selectin (10 Ϫ3 M) for 15 min, cocultured with HL-60 cells, and then imaged with the digital fluorescent camera as described.
Statistical Analyses. Data are expressed as the mean Ϯ SD. Statistical comparisons were made by analysis of variance followed by a Bonferroni's t test for multiple comparison. A P value Ͻ0.05 was considered significant.
